Celon Pharma SA (CLN) Stock Statistics & Valuation Metrics

Celon Pharma SA has a market cap or net worth of zł1.23B. The enterprise value is zł1.20B.

Celon Pharma SA has 53,856,500 shares outstanding. The number of shares has decreased by -2.65% in one year.

Celon Pharma SA’s return on equity (ROE) is -0.08 and return on invested capital (ROIC) is -6.92%.

The current PE Ratio of Celon Pharma SA is 74.9. Celon Pharma SA’s PEG ratio is -2.02.

In the last 12 months, Celon Pharma SA had revenue of 176.62M and earned -34.45M in profits. Earnings per share was -0.66.

In the last 12 months, operating cash flow was -9.38M and capital expenditures -44.06M, giving a free cash flow of -53.44M billion.

Celon Pharma SA pays an annual dividend of zł0.298, resulting in a dividend yield of 0.35%

Celon Pharma SA upcoming earnings date is Nov 19, 2025, TBA (Confirmed).

Celon Pharma SA as a current ratio of 1.84, with Debt / Equity ratio of 4.72%

In the past 12 months, Celon Pharma SA has paid -4.92M in taxes.

Celon Pharma SA EV to EBITDA ratio is 93.41, with an EV/FCF ratio of -40.95.

Celon Pharma SA has zł38.98M in cash and marketable securities with zł19.88M in debt, giving a net cash position of zł19.10M billion.

Gross margin is 63.56%, with operating margin of -20.84%, and net profit margin of -19.50%.

The average price target for Celon Pharma SA is zł21.01, which is 11.43% higher than the current price. The consensus rating is Hold